Marker Therapeutics, Inc.

Category: Press Releases

Tapimmune Announces Development Of Advanced Immunotherapeutic Vaccine Expression And Delivery System

TapImmune is pleased to announce development of a revolutionary cost effective immunotherapeutic vaccine expression and delivery system. The novel platform is termed TapImmune’s PolyStart™ technology and has been strategically designed to directly enhance the immune system’s ability to stimulate either or BOTH cytotoxic killer and helper T-cell reactive proprietary peptides, known and expected to be associated with one, or more importantly, ANY cancer, infectious disease or bio-threat.
Read More

TapImmune Chairman Provides Corporate Update on Development Programs & Collaborations

It is my pleasure to provide an update to existing and potentially new shareholders on the progress we have made over the past few months. Highlights from the below detailed update include: Positive progress at the MAYO clinic on the phase 1 HER2/neu clinical trial with interim results expected in the near term.
Read More

TapImmune Provides Operational Update including Human Data Supporting Use of TAP Based Cancer Vaccine Company Establishes Laboratory Facilities in Vancouver Canada

ANCOUVER, Canada, 31 July, 2007 – TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, opens new laboratory facilities and provides this update to shareholders.
Read More

TapImmune Inc. Announces Availability of New Investor Information

VANCOUVER, British Columbia, July 17, 2007 (PRIME NEWSWIRE) — TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced today that it has launched a new corporate website with links to media features on its technologies.
Read More

TapImmune Inc. Announces Acquisition of Core TAP Technologies and Intellectual Property from The University of British Columbia

New Name to Reflect a New Direction and Independent Operation VANCOUVER, BC – TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced today that it has fulfilled its financial obligation to The University of British Columbia for the proposed acquisition of its key Transporter Associated with Antigen Processing (TAP) technology platform and patents.
Read More